Glenmark Life Sciences Limited
NSE:GLS.NS
1271.65 (INR) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 22,832.14 | 21,612.2 | 21,232.14 | 18,851.65 | 15,373.13 | 14,050.26 | 2.48 |
| Cost of Revenue
| 10,020.1 | 10,140.88 | 10,428.87 | 9,054.97 | 6,904.58 | 6,264.43 | 2.37 |
| Gross Profit
| 12,812.04 | 11,471.32 | 10,803.27 | 9,796.68 | 8,468.55 | 7,785.83 | 0.11 |
| Gross Profit Ratio
| 0.561 | 0.531 | 0.509 | 0.52 | 0.551 | 0.554 | 0.044 |
| Reseach & Development Expenses
| 752.97 | 651.77 | 571.96 | 2.9 | 400.28 | 1.44 | 0 |
| General & Administrative Expenses
| 0 | 91.5 | 80.86 | 74.24 | 71.45 | 92.43 | 0 |
| Selling & Marketing Expenses
| 0 | 246.18 | 317.81 | 337.88 | 263.24 | 267.13 | 0 |
| SG&A
| 3,488.02 | 337.68 | 398.67 | 412.12 | 334.69 | 359.56 | 0.24 |
| Other Expenses
| 120.42 | 289.57 | 3.19 | 3.81 | 3.96 | 0.33 | 0 |
| Operating Expenses
| 6,604.1 | 5,469.33 | 5,014.01 | 4,179.45 | 4,030.33 | 3,693.08 | 0.24 |
| Operating Income
| 6,328.36 | 6,007.57 | 5,789.26 | 5,617.23 | 4,438.22 | 2,358.03 | -0.13 |
| Operating Income Ratio
| 0.277 | 0.278 | 0.273 | 0.298 | 0.289 | 0.168 | -0.052 |
| Total Other Income Expenses Net
| -15.46 | 278.52 | -140.01 | -907.79 | -227.55 | -75.06 | 0.01 |
| Income Before Tax
| 6,312.9 | 6,286.09 | 5,649.25 | 4,709.44 | 4,210.67 | 4,038.39 | -0.13 |
| Income Before Tax Ratio
| 0.276 | 0.291 | 0.266 | 0.25 | 0.274 | 0.287 | -0.052 |
| Income Tax Expense
| 1,604.02 | 1,616.48 | 1,462.01 | 1,193.63 | 1,079.69 | 1,111.66 | 4.21 |
| Net Income
| 4,708.88 | 4,669.61 | 4,187.24 | 3,515.81 | 3,130.98 | 2,926.73 | -4.34 |
| Net Income Ratio
| 0.206 | 0.216 | 0.197 | 0.186 | 0.204 | 0.208 | -1.75 |
| EPS
| 38.43 | 38.11 | 35.63 | 32.61 | 29.04 | 23.89 | -0.04 |
| EPS Diluted
| 38.38 | 38.11 | 35.63 | 32.61 | 29.04 | 23.89 | -0.04 |
| EBITDA
| 6,862.88 | 6,712.5 | 6,315.07 | 5,924.69 | 4,851.8 | 4,304.6 | -0.13 |
| EBITDA Ratio
| 0.301 | 0.311 | 0.297 | 0.314 | 0.316 | 0.306 | -0.052 |